Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors
about
Peptidylarginine deiminases in citrullination, gene regulation, health and pathogenesisThe role of epigenetics in resistance to Cisplatin chemotherapy in lung cancerThe induction of microRNA-16 in colon cancer cells by protein arginine deiminase inhibition causes a p53-dependent cell cycle arrestPotential role for PAD2 in gene regulation in breast cancer cells.Citrullination of myofilament proteins in heart failure.Investigating citrullinated proteins in tumour cell linesSynovial detection and autoantibody reactivity of processed citrullinated isoforms of vimentin in inflammatory arthritides.Increased PADI4 expression in blood and tissues of patients with malignant tumorsPotential role for peptidylarginine deiminase 2 (PAD2) in citrullination of canine mammary epithelial cell histones.The Type IX Secretion System (T9SS): Highlights and Recent Insights into Its Structure and Function.Substrate specificity and kinetic studies of PADs 1, 3, and 4 identify potent and selective inhibitors of protein arginine deiminase 3.NETosis: a new factor in tumor progression and cancer-associated thrombosisCitrullination of DNMT3A by PADI4 regulates its stability and controls DNA methylationPAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps.Expression of peptidylarginine deiminase type 4 in ovarian tumors.Anti-citrulline antibodies in the diagnosis and prognosis of rheumatoid arthritis: evolving concepts.Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitorInvestigating the pathogenic role of PADI4 in oesophageal cancerInhibiting protein arginine deiminases has antioxidant consequences.Chemical biology of protein arginine modifications in epigenetic regulationPeptidylarginine deiminase type 4 deficiency reduced arthritis severity in a glucose-6-phosphate isomerase-induced arthritis model.Potential role of peptidylarginine deiminase enzymes and protein citrullination in cancer pathogenesis.Protein arginine deiminase 4: evidence for a reverse protonation mechanism.Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure.A novel PAD4/SOX4/PU.1 signaling pathway is involved in the committed differentiation of acute promyelocytic leukemia cells into granulocytic cellsPriming of neutrophils toward NETosis promotes tumor growth.Dysregulation of PAD4-mediated citrullination of nuclear GSK3β activates TGF-β signaling and induces epithelial-to-mesenchymal transition in breast cancer cells.PADI2 gene confers susceptibility to breast cancer and plays tumorigenic role via ACSL4, BINC3 and CA9 signalingProtective effect of Cl-amidine against CLP-induced lethal septic shock in miceRole of peptidylarginine deiminase type 4 in gastric cancer.PADI4 has genetic susceptibility to gastric carcinoma and upregulates CXCR2, KRT14 and TNF-α expression levels.Molecular Interplay between the Dimer Interface and the Substrate-Binding Site of Human Peptidylarginine Deiminase 4.Looking for the best anti-colitis medicine: A comparative analysis of current and prospective compounds.Post-translational modifications of the extracellular matrix are key events in cancer progression: opportunities for biochemical marker development.The application of targeted mass spectrometry-based strategies to the detection and localization of post-translational modifications.A novel role for peptidylarginine deiminases in microvesicle release reveals therapeutic potential of PAD inhibition in sensitizing prostate cancer cells to chemotherapy.Mechanistic studies of protein arginine deiminase 2: evidence for a substrate-assisted mechanismSeeing citrulline: development of a phenylglyoxal-based probe to visualize protein citrullination.PAD1 promotes epithelial-mesenchymal transition and metastasis in triple-negative breast cancer cells by regulating MEK1-ERK1/2-MMP2 signaling.PAD4: pathophysiology, current therapeutics and future perspective in rheumatoid arthritis.
P2860
Q26991867-A11F0677-6704-40A1-BAD5-07C2DE1653B2Q28387891-3326E2C9-A8BD-4277-B769-0B70AA8BCBECQ28484878-6F99214C-D7CB-4DD8-9C25-48AA06797FFAQ28728858-3C97FD5C-4834-498E-A30F-2A9DE62C0862Q30670009-8217A6B7-5B14-4989-BF54-79FB7A8E3CC3Q31140984-ADA5AEB6-F5BD-4A20-B731-9F761034FAF8Q33322989-4923D9D9-7C19-4DA9-BE55-92AB46BB93D1Q33404427-06BB2E92-4E36-45C8-8E0B-4AEBB2BED865Q33644443-8553E543-03D8-49BF-B610-C0E7B390F753Q33729399-3189A020-68F5-405B-A5F7-138692FA0B58Q33907872-544CA9BD-467C-4874-9F50-15064D0A195DQ33957938-F27F7E41-E4A8-4355-99F9-267E32F28D40Q33983526-82A232B7-7E76-4DEA-83AD-83008DA4F173Q34096547-16B4D758-6AC0-4435-B2FB-118BE312A7AEQ34111421-CB537034-896D-4A61-BBD5-6467114452B5Q34635933-A5833047-8B50-48ED-AE25-D7064605F9ECQ35057027-60FA6FE3-0BE9-45D4-A9CA-140711CB8920Q35059255-195FEAB2-FE3A-4A8E-BBCB-44F12FBCAA19Q35197879-A0CFBBFA-DD80-45E4-AAFF-032ED2DB1C98Q35722457-79D7B681-FF69-4485-8D41-1460740A9002Q35979391-1B094969-8261-4928-A857-490E01E2EFF5Q36277576-1B266A35-351A-424A-B0C5-011678AA13C6Q36402001-E8A4C052-5FBD-45A0-804B-A47640C09530Q36672445-0CF82D3E-B196-4BF6-A54C-23124346E612Q36772066-85DBC038-E447-435E-9CDF-7BE8FCB962AAQ37012590-FEC47757-72C4-4FB7-8F9D-76A51BB58B8BQ37031694-CDBAEF6F-111C-4AEE-884C-96609E78A6F5Q37138400-FB643BB5-E3CC-4CB8-A343-C0D37439C64BQ37397289-48110EB9-5C68-4D4D-8BB9-6AB01992BD23Q37406509-935D6CA1-CC34-43FA-B3DA-296DFCE094D7Q37641748-26AACD27-23A4-4D06-A88C-747862CEDA75Q37648828-2F3ADFDE-E2A0-480A-BFB8-5F5BF014A0E7Q37702204-51E131A5-C9E9-4D06-92EB-4660A79F2CB6Q37867110-E33DFB8A-53B4-498B-87A1-96F784D0B2FEQ38204953-4F9CFAA8-5079-493B-A5EB-69785E55C73CQ38443364-378E5975-792B-4E52-B363-61D15894A87CQ38448551-B80472E9-96CB-4B8C-9CA9-05AD6A91F5F5Q38456823-95DA49C1-AF71-4B88-9F36-8F71F4576FD5Q38606630-CDC261E7-640D-42E3-AEB6-1548B2D1B34DQ38747640-DBDD56DB-567E-453A-9D0D-8752103FB8F4
P2860
Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors
@ast
Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors
@en
Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors
@nl
type
label
Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors
@ast
Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors
@en
Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors
@nl
prefLabel
Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors
@ast
Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors
@en
Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors
@nl
P3181
P356
P1476
Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors
@en
P2093
Jinxiang Han
Xiaotian Chang
P2860
P304
P3181
P356
10.1002/MC.20169
P407
P577
2006-03-01T00:00:00Z